- Home
- ELVN vs DYN Comparison
ELVN vs DYN Comparison
Compare ELVN & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- DYN
- Stock Information
- Founded
- ELVN 2016
- DYN 1984
- Country
- ELVN United States
- DYN United States
- Employees
- ELVN N/A
- DYN N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- DYN Medicinal Chemicals and Botanical Products
- Sector
- ELVN Health Care
- DYN Health Care
- Exchange
- ELVN Nasdaq
- DYN Nasdaq
- Market Cap
- ELVN 927.8M
- DYN 848.8M
- IPO Year
- ELVN 2020
- DYN 2020
- Fundamental
- Price
- ELVN $18.42
- DYN $11.41
- Analyst Decision
- ELVN Strong Buy
- DYN Strong Buy
- Analyst Count
- ELVN 4
- DYN 12
- Target Price
- ELVN $39.25
- DYN $47.00
- AVG Volume (30 Days)
- ELVN 260.6K
- DYN 2.9M
- Earning Date
- ELVN 05-13-2025
- DYN 05-08-2025
- Dividend Yield
- ELVN N/A
- DYN N/A
- EPS Growth
- ELVN N/A
- DYN N/A
- EPS
- ELVN N/A
- DYN N/A
- Revenue
- ELVN N/A
- DYN N/A
- Revenue This Year
- ELVN N/A
- DYN N/A
- Revenue Next Year
- ELVN N/A
- DYN N/A
- P/E Ratio
- ELVN N/A
- DYN N/A
- Revenue Growth
- ELVN N/A
- DYN N/A
- 52 Week Low
- ELVN $13.30
- DYN $6.36
- 52 Week High
- ELVN $30.03
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- ELVN 47.86
- DYN 55.69
- Support Level
- ELVN $17.76
- DYN $9.17
- Resistance Level
- ELVN $20.79
- DYN $12.47
- Average True Range (ATR)
- ELVN 1.37
- DYN 0.96
- MACD
- ELVN 0.12
- DYN 0.13
- Stochastic Oscillator
- ELVN 45.39
- DYN 67.88
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.